Friday Merck & Company (MRK) $MRK opened at 59.47 hitting the high price of 59.53 and a day low of 57.94 with a total volume of 12,079,500. MRK had a previous close of 59.62 and has been seeing an average volume of 11,606,436.
Overall Average: 88% Buy
Recent stock forum discussions about MRK http://investorshangout.com/search?q=MRK&...mp;yt0=Go!
1 Pipeline All Investors Need to Know
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 03, 4:05PM CDT
In this segment from Tuesday's Market Checkup , Motley Fool health-care analysts David Williamson and Michael Douglass look at Merck , and why its pipeline is one investors should be excited about today. Amazingly, Merck looks as though it will... (full story)
Dividend Investors Are Loving This Dow Strategy In 2014
Dan Caplinger, The Motley Fool - Motley Fool - Sat May 03, 10:02AM CDT
The Dow Jones Industrials finally set a new record high this past week, climbing four points above its previous record level at the end of 2013. But with the Dow having moved down again to finish the week down, stock market investors are getting... (full story)
Merck Earnings: What Investors Need to Know
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 03, 9:34AM CDT
The big pharma stocks are all reporting their first-quarter results, and Merck 's beginning of 2014 was decidedly mixed. The company missed Wall Street expectations on the top line as revenue declined 4% thanks in part to generic competition, but... (full story)
The Dow Misses a New Record as Merck, Pfizer, and J&J Lag
Dan Caplinger, The Motley Fool - Motley Fool - Fri May 02, 8:05PM CDT
After climbing to potential new-record levels at the open, the Dow Jones Industrials closed down almost 46 points on Friday, with trouble in Ukraine heating up and prompting an emergency meeting of the U.N. Security Council in response to violence... (full story)
Endocyte
at Investor's Business Daily - Fri May 02, 5:58PM CDT
Endocyte (ECYT) and its big-pharma partner Merck (MRK) ended trials of ovarian-cancer treatment Vynfinit after interim analysis showed no improvement in patients' progression-free survival. Endocyte shares fell 62%. Merck fell 2%. (full story)
Down 62%: Is Endocyte a Bad News Buy?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri May 02, 5:30PM CDT
Endocyte shares were hammered today, after the data safety monitoring board halted a phase 3 trial for its flagship drug after concluding that the drug would not achieve its primary endpoint. Vintafolide was being tested for platinum-resistant... (full story)
Stocks Drop as Jobs Pop Is Offset by Troubling Details
at The Street - Fri May 02, 3:23PM CDT
U.S. stocks close lower Friday, erasing early gains after April's jobs report shows a lower work force participation rate. The United Nations is holding an emergency meeting over Ukraine as tensions rise in the region. (full story)
FDA panel pans over-the-counter Singulair proposal
AP - Fri May 02, 3:14PM CDT
WASHINGTON (AP) — Federal health advisers have voted against a Merck proposal to sell its prescription respiratory pill Singulair as an over-the-counter allergy medication. (full story)
Big Pharma Deals Send Dow Lower
Travis Hoium, The Motley Fool - Motley Fool - Fri May 02, 2:30PM CDT
On a day when the Department of Labor issued a seemingly great jobs report, the Dow Jones Industrial Average was off 0.28% late in trading. A big reason is the index's two big pharma companies, Merck and Pfizer , falling as acquisition and... (full story)
Merck's Drug Failure, Chevron's Earnings Plunge Lead the Dow's Fall
Dan Carroll, The Motley Fool - Motley Fool - Fri May 02, 1:38PM CDT
The market is on the way to closing out the week in the red despite strong numbers in the government's Apriil jobs report. The Dow Jones Industrial Average was down 52 points as of 2:30 p.m. EDT, with most blue-chip stocks in the red and the... (full story)
Pfizer Inc. Earnings: Can They Grow Without AstraZeneca?
Dan Caplinger, The Motley Fool - Motley Fool - Fri May 02, 1:30PM CDT
On Monday, Pfizer will release its quarterly report, and despite strong markets over the past year, the pharmaceutical giant's shares have stayed in a tight range. Investors are pondering how Pfizer can best foster growth in an increasingly... (full story)
Why Rising Dividends in Big Pharma May Be Bad News for Investors
Sean Williams, The Motley Fool - Motley Fool - Fri May 02, 1:10PM CDT
According to research firm FactSet, which issues a quarterly report on dividend payouts within the S&P 500 , 418 of the S&P's 500 components paid a dividend in the fourth quarter. Not only did this mixture of 500 large- and medium-cap... (full story)
Why Endocyte, Inc. Shares Were Throttled
Sean Williams, The Motley Fool - Motley Fool - Fri May 02, 12:55PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Endocyte , a biopharmaceutical company... (full story)
Boeing Jumps While Merck Holds Down the Dow
Dan Dzombak, The Motley Fool - Motley Fool - Fri May 02, 12:34PM CDT
Boeing is trying to push the Dow Jones Industrial Average up, but a fall in pharmaceutical stocks is keeping the Dow Jones flat today. As of 1:25 p.m. EDT the Dow was down 31 points to 16,528. The S&P 500 was flat at 1,883 points. The... (full story)
Stock Narrowly Mixed; Wynn Nears 50-Day Average
at Investor's Business Daily - Fri May 02, 12:29PM CDT
Stocks improved slightly and turned mixed Friday afternoon. Indexes have wavered amid a surprisingly strong job report and more tension in Ukraine. The Nasdaq and the S&P 500 were up 0.2% and 0.1%, respectively. But the Dow Jones industrial average... (full story)
Endocyte tumbles on ovarian cancer study
AP - Fri May 02, 11:14AM CDT
NEW YORK (AP) — Merck and Endocyte said Friday that they are stopping a clinical trial of an experimental cancer drug, sending Endocyte shares plunging. (full story)
Dow 30 Stock Roundup: Microsoft, Merck, Exxon Beat, JNJ Ups Dividend - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri May 02, 10:50AM CDT
The blue chip index had an excellent week on the back of bullish economic data and earnings numbers. (full story)
Merck, Endocyte Stop Trial Of Ovarian Cancer Drug
at Investor's Business Daily - Fri May 02, 10:09AM CDT
Biotech firm Endocyte (ECYT) and its big-pharma partner Merck (MRK) stopped a clinical trial of their ovarian-cancer drug on grounds of "futility" Friday, sending both stocks tumbling on the stock market today.The companies said that the Data Safety... (full story)
Should You Buy Tesaro After Its Earnings Miss?
Leo Sun, The Motley Fool - Motley Fool - Fri May 02, 8:30AM CDT
Tesaro , a development-stage biotech, reported its first-quarter earnings on April 30. Tesaro reported a net loss of $49.8 million, or $1.43 per share -- a steep drop from the loss of $18.9 million, or $0.66 per share, it posted in the... (full story)
Endocyte Falls on Ovarian Cancer Drug Blowup
at The Street - Fri May 02, 8:01AM CDT
European regulators are likely to rescind the conditional approval of Endocyte's ovarian cancer drug Vynfinit following the failure of a phase III study. (full story)
Overall Average: 88% Buy
Recent stock forum discussions about MRK http://investorshangout.com/search?q=MRK&...mp;yt0=Go!
1 Pipeline All Investors Need to Know
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 03, 4:05PM CDT
In this segment from Tuesday's Market Checkup , Motley Fool health-care analysts David Williamson and Michael Douglass look at Merck , and why its pipeline is one investors should be excited about today. Amazingly, Merck looks as though it will... (full story)
Dividend Investors Are Loving This Dow Strategy In 2014
Dan Caplinger, The Motley Fool - Motley Fool - Sat May 03, 10:02AM CDT
The Dow Jones Industrials finally set a new record high this past week, climbing four points above its previous record level at the end of 2013. But with the Dow having moved down again to finish the week down, stock market investors are getting... (full story)
Merck Earnings: What Investors Need to Know
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 03, 9:34AM CDT
The big pharma stocks are all reporting their first-quarter results, and Merck 's beginning of 2014 was decidedly mixed. The company missed Wall Street expectations on the top line as revenue declined 4% thanks in part to generic competition, but... (full story)
The Dow Misses a New Record as Merck, Pfizer, and J&J Lag
Dan Caplinger, The Motley Fool - Motley Fool - Fri May 02, 8:05PM CDT
After climbing to potential new-record levels at the open, the Dow Jones Industrials closed down almost 46 points on Friday, with trouble in Ukraine heating up and prompting an emergency meeting of the U.N. Security Council in response to violence... (full story)
Endocyte
at Investor's Business Daily - Fri May 02, 5:58PM CDT
Endocyte (ECYT) and its big-pharma partner Merck (MRK) ended trials of ovarian-cancer treatment Vynfinit after interim analysis showed no improvement in patients' progression-free survival. Endocyte shares fell 62%. Merck fell 2%. (full story)
Down 62%: Is Endocyte a Bad News Buy?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri May 02, 5:30PM CDT
Endocyte shares were hammered today, after the data safety monitoring board halted a phase 3 trial for its flagship drug after concluding that the drug would not achieve its primary endpoint. Vintafolide was being tested for platinum-resistant... (full story)
Stocks Drop as Jobs Pop Is Offset by Troubling Details
at The Street - Fri May 02, 3:23PM CDT
U.S. stocks close lower Friday, erasing early gains after April's jobs report shows a lower work force participation rate. The United Nations is holding an emergency meeting over Ukraine as tensions rise in the region. (full story)
FDA panel pans over-the-counter Singulair proposal
AP - Fri May 02, 3:14PM CDT
WASHINGTON (AP) — Federal health advisers have voted against a Merck proposal to sell its prescription respiratory pill Singulair as an over-the-counter allergy medication. (full story)
Big Pharma Deals Send Dow Lower
Travis Hoium, The Motley Fool - Motley Fool - Fri May 02, 2:30PM CDT
On a day when the Department of Labor issued a seemingly great jobs report, the Dow Jones Industrial Average was off 0.28% late in trading. A big reason is the index's two big pharma companies, Merck and Pfizer , falling as acquisition and... (full story)
Merck's Drug Failure, Chevron's Earnings Plunge Lead the Dow's Fall
Dan Carroll, The Motley Fool - Motley Fool - Fri May 02, 1:38PM CDT
The market is on the way to closing out the week in the red despite strong numbers in the government's Apriil jobs report. The Dow Jones Industrial Average was down 52 points as of 2:30 p.m. EDT, with most blue-chip stocks in the red and the... (full story)
Pfizer Inc. Earnings: Can They Grow Without AstraZeneca?
Dan Caplinger, The Motley Fool - Motley Fool - Fri May 02, 1:30PM CDT
On Monday, Pfizer will release its quarterly report, and despite strong markets over the past year, the pharmaceutical giant's shares have stayed in a tight range. Investors are pondering how Pfizer can best foster growth in an increasingly... (full story)
Why Rising Dividends in Big Pharma May Be Bad News for Investors
Sean Williams, The Motley Fool - Motley Fool - Fri May 02, 1:10PM CDT
According to research firm FactSet, which issues a quarterly report on dividend payouts within the S&P 500 , 418 of the S&P's 500 components paid a dividend in the fourth quarter. Not only did this mixture of 500 large- and medium-cap... (full story)
Why Endocyte, Inc. Shares Were Throttled
Sean Williams, The Motley Fool - Motley Fool - Fri May 02, 12:55PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Endocyte , a biopharmaceutical company... (full story)
Boeing Jumps While Merck Holds Down the Dow
Dan Dzombak, The Motley Fool - Motley Fool - Fri May 02, 12:34PM CDT
Boeing is trying to push the Dow Jones Industrial Average up, but a fall in pharmaceutical stocks is keeping the Dow Jones flat today. As of 1:25 p.m. EDT the Dow was down 31 points to 16,528. The S&P 500 was flat at 1,883 points. The... (full story)
Stock Narrowly Mixed; Wynn Nears 50-Day Average
at Investor's Business Daily - Fri May 02, 12:29PM CDT
Stocks improved slightly and turned mixed Friday afternoon. Indexes have wavered amid a surprisingly strong job report and more tension in Ukraine. The Nasdaq and the S&P 500 were up 0.2% and 0.1%, respectively. But the Dow Jones industrial average... (full story)
Endocyte tumbles on ovarian cancer study
AP - Fri May 02, 11:14AM CDT
NEW YORK (AP) — Merck and Endocyte said Friday that they are stopping a clinical trial of an experimental cancer drug, sending Endocyte shares plunging. (full story)
Dow 30 Stock Roundup: Microsoft, Merck, Exxon Beat, JNJ Ups Dividend - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri May 02, 10:50AM CDT
The blue chip index had an excellent week on the back of bullish economic data and earnings numbers. (full story)
Merck, Endocyte Stop Trial Of Ovarian Cancer Drug
at Investor's Business Daily - Fri May 02, 10:09AM CDT
Biotech firm Endocyte (ECYT) and its big-pharma partner Merck (MRK) stopped a clinical trial of their ovarian-cancer drug on grounds of "futility" Friday, sending both stocks tumbling on the stock market today.The companies said that the Data Safety... (full story)
Should You Buy Tesaro After Its Earnings Miss?
Leo Sun, The Motley Fool - Motley Fool - Fri May 02, 8:30AM CDT
Tesaro , a development-stage biotech, reported its first-quarter earnings on April 30. Tesaro reported a net loss of $49.8 million, or $1.43 per share -- a steep drop from the loss of $18.9 million, or $0.66 per share, it posted in the... (full story)
Endocyte Falls on Ovarian Cancer Drug Blowup
at The Street - Fri May 02, 8:01AM CDT
European regulators are likely to rescind the conditional approval of Endocyte's ovarian cancer drug Vynfinit following the failure of a phase III study. (full story)
